Q93033 (IGSF2_HUMAN) Reviewed, UniProtKB/Swiss-Prot

Names and origin

Protein names

Recommended name:
Immunoglobulin superfamily member 2
Short name=IgSF2

Alternative name(s):
Cell surface glycoprotein V7
Glu-Trp-Ile EWI motif-containing protein 101
Short name=EWI-101
CD_antigen=CD101

Gene names

Name:	CD101
Synonyms:	EWI101, IGSF2, V7

Organism

Homo sapiens (Human)

Taxonomic identifier

9606 [NCBI]

Taxonomic lineage

Eukaryota › Metazoa › Chordata › Craniata › Vertebrata › Euteleostomi › Mammalia › Eutheria › Euarchontoglires › Primates › Haplorrhini › Catarrhini › Hominidae › Homo

Protein attributes

Sequence length	1021 AA.
Sequence status	Complete.
Sequence processing	The displayed sequence is further processed into a mature form.
Protein existence	Evidence at protein level

General annotation (Comments)

Function	Plays a role as inhibitor of T-cells proliferation induced by CD3. Inhibits expression of IL2RA on activated T-cells and secretion of IL2. Inhibits tyrosine kinases that are required for IL2 production and cellular proliferation. Inhibits phospholipase C-gamma-1/PLCG1 phosphorylation and subsequent CD3-induced changes in intracellular free calcium. Prevents nuclear translocation of nuclear factor of activated T-cell to the nucleus. Plays a role in the inhibition of T-cell proliferation via IL10 secretion by cutaneous dendritic cells. May be a marker of CD4+ CD56+ leukemic tumor cells. Ref.3 Ref.4 Ref.5 Ref.6 Ref.7 Ref.10
Subcellular location	Membrane; Single-pass type I membrane protein Potential.
Tissue specificity	Expressed in lung, thymus and small intestine. Detected in cutaneous dendritic cells, activated T-cells, monocytes and granulocytes as well as with epithelial cells with dendritic morphology. Expressed in some leukemic cells, the CD4+ CD56+ blastic tumor cells, as well as in Langerhans cells from LCH (Langerhans cell histiocytosis) patients. Ref.1 Ref.3 Ref.5 Ref.8 Ref.10
Post-translational modification	N-glycosylated. Ref.3
Sequence similarities	Contains 7 Ig-like C2-type (immunoglobulin-like) domains.

Ontologies

Keywords
Cellular component	Membrane
Coding sequence diversity	Polymorphism
Domain	Immunoglobulin domain Repeat Signal Transmembrane Transmembrane helix
PTM	Disulfide bond Glycoprotein
Technical term	Complete proteome Reference proteome
Gene Ontology (GO)
Biological process	cell surface receptor linked signaling pathway Traceable author statement. Source: ProtInc
Cellular component	integral to membrane Traceable author statement. Source: ProtInc plasma membrane Traceable author statement. Source: ProtInc
Molecular function	hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in cyclic amides Inferred from electronic annotation. Source: InterPro
Complete GO annotation...

Sequence annotation (Features)

	Feature key	Position(s)	Length	Description	Graphical view	Feature identifier
Molecule processing
	Signal peptide	1 – 20	20	Potential
	Chain	21 – 1021	1001	Immunoglobulin superfamily member 2		PRO_0000253539
Regions
	Topological domain	21 – 954	934	Extracellular Potential
	Transmembrane	955 – 975	21	Helical; Potential
	Topological domain	976 – 1021	46	Cytoplasmic Potential
	Domain	22 – 139	118	Ig-like C2-type 1
	Domain	144 – 265	122	Ig-like C2-type 2
	Domain	279 – 389	111	Ig-like C2-type 3
	Domain	408 – 525	118	Ig-like C2-type 4
	Domain	541 – 651	111	Ig-like C2-type 5
	Domain	656 – 794	139	Ig-like C2-type 6
	Domain	808 – 925	118	Ig-like C2-type 7
	Motif	253 – 255	3	EWI motif
Amino acid modifications
	Glycosylation	44	1	N-linked (GlcNAc...) Potential
	Glycosylation	322	1	N-linked (GlcNAc...) Potential
	Disulfide bond	43 ↔ 121		By similarity
	Disulfide bond	168 ↔ 249		By similarity
	Disulfide bond	304 ↔ 377		By similarity
	Disulfide bond	434 ↔ 511		By similarity
	Disulfide bond	562 ↔ 640		By similarity
	Disulfide bond	697 ↔ 778		By similarity
	Disulfide bond	834 ↔ 909		By similarity
Natural variations
	Natural variant	157	1	G → S. Corresponds to variant rs34999087 [ dbSNP | Ensembl ].		VAR_054434
	Natural variant	225	1	N → S. Corresponds to variant rs3754112 [ dbSNP | Ensembl ].		VAR_028371
	Natural variant	415	1	M → V. Ref.1 Corresponds to variant rs2249265 [ dbSNP | Ensembl ].		VAR_028372
	Natural variant	518	1	R → Q. Corresponds to variant rs17235766 [ dbSNP | Ensembl ].		VAR_028373
	Natural variant	525	1	S → R. Corresponds to variant rs17235773 [ dbSNP | Ensembl ].		VAR_028374
	Natural variant	631	1	T → S. Corresponds to variant rs34510762 [ dbSNP | Ensembl ].		VAR_054435
	Natural variant	933	1	R → Q. Corresponds to variant rs12093834 [ dbSNP | Ensembl ].		VAR_054436
	Natural variant	955	1	L → F. Corresponds to variant rs34223095 [ dbSNP | Ensembl ].		VAR_054437
	Natural variant	965	1	V → I. Corresponds to variant rs12097758 [ dbSNP | Ensembl ].		VAR_028375
	Natural variant	988	1	R → C. Corresponds to variant rs12067543 [ dbSNP | Ensembl ].		VAR_028376
	Natural variant	992	1	R → W. Corresponds to variant rs34248572 [ dbSNP | Ensembl ].		VAR_054438
Experimental info
	Sequence conflict	91	1	S → G in CAA83923. Ref.1
	Sequence conflict	129	1	K → N in CAA83923. Ref.1
	Sequence conflict	135	1	S → R in CAA83923. Ref.1
	Sequence conflict	352	1	V → L in CAA83923. Ref.1
	Sequence conflict	684	1	V → G in CAA83923. Ref.1

Sequences

	Sequence		Length	Mass (Da)
	Q93033 [UniParc]. Last modified February 10, 2009. Version 2. Checksum: 12A07C648D21EB91	FASTA	1,021	115,109
	10 20 30 40 50 60 MAGISYVASF FLLLTKLSIG QREVTVQKGP LFRAEGYPVS IGCNVTGHQG PSEQHFQWSV 70 80 90 100 110 120 YLPTNPTQEV QIISTKDAAF SYAVYTQRVR SGDVYVERVQ GNSVLLHISK LQMKDAGEYE 130 140 150 160 170 180 CHTPNTDEKY YGSYSAKTNL IVIPDTLSAT MSSQTLGKEE GEPLALTCEA SKATAQHTHL 190 200 210 220 230 240 SVTWYLTQDG GGSQATEIIS LSKDFILVPG PLYTERFAAS DVQLNKLGPT TFRLSIERLQ 250 260 270 280 290 300 SSDQGQLFCE ATEWIQDPDE TWMFITKKQT DQTTLRIQPA VKDFQVNITA DSLFAEGKPL 310 320 330 340 350 360 ELVCLVVSSG RDPQLQGIWF FNGTEIAHID AGGVLGLKND YKERASQGEL QVSKLGPKAF 370 380 390 400 410 420 SLKIFSLGPE DEGAYRCVVA EVMKTRTGSW QVLQRKQSPD SHVHLRKPAA RSVVMSTKNK 430 440 450 460 470 480 QQVVWEGETL AFLCKAGGAE SPLSVSWWHI PRDQTQPEFV AGMGQDGIVQ LGASYGVPSY 490 500 510 520 530 540 HGNTRLEKMD WATFQLEITF TAITDSGTYE CRVSEKSRNQ ARDLSWTQKI SVTVKSLESS 550 560 570 580 590 600 LQVSLMSRQP QVMLTNTFDL SCVVRAGYSD LKVPLTVTWQ FQPASSHIFH QLIRITHNGT 610 620 630 640 650 660 IEWGNFLSRF QKKTKVSQSL FRSQLLVHDA TEEETGVYQC EVEVYDRNSL YNNRPPRASA 670 680 690 700 710 720 ISHPLRIAVT LPESKLKVNS RSQVQELSIN SNTDIECSIL SRSNGNLQLA IIWYFSPVST 730 740 750 760 770 780 NASWLKILEM DQTNVIKTGD EFHTPQRKQK FHTEKVSQDL FQLHILNVED SDRGKYHCAV 790 800 810 820 830 840 EEWLLSTNGT WHKLGEKKSG LTELKLKPTG SKVRVSKVYW TENVTEHREV AIRCSLESVG 850 860 870 880 890 900 SSATLYSVMW YWNRENSGSK LLVHLQHDGL LEYGEEGLRR HLHCYRSSST DFVLKLHQVE 910 920 930 940 950 960 MEDAGMYWCR VAEWQLHGHP SKWINQASDE SQRMVLTVLP SEPTLPSRIC SSAPLLYFLF 970 980 990 1000 1010 1020 ICPFVLLLLL LISLLCLYWK ARKLSTLRSN TRKEKALWVD LKEAGGVTTN RREDEEEDEG N

References

	« Hide 'large scale' referencesShow 'large scale' references »
[1]	"V7, a novel leukocyte surface protein that participates in T cell activation. II. Molecular cloning and characterization of the V7 gene." Ruegg C.L., Rivas A., Madani N.D., Zeitung J., Laus R., Engleman E.G. J. Immunol. 154:4434-4443(1995) [PubMed: 7722300] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, VARIANT VAL-415.
[2]	"The DNA sequence and biological annotation of human chromosome 1." Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K. , Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R. Nature 441:315-321(2006) [PubMed: 16710414] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
[3]	"V7, a novel leukocyte surface protein that participates in T cell activation. I. Tissue distribution and functional studies." Rivas A., Ruegg C.L., Zeitung J., Laus R., Warnke R., Benike C., Engleman E.G. J. Immunol. 154:4423-4433(1995) [PubMed: 7722299] [Abstract] Cited for: FUNCTION, GLYCOSYLATION, TISSUE SPECIFICITY.
[4]	"Ligation of the V7 molecule on T cells blocks anergy induction through a CD28-independent mechanism." Soares L.R.B., Rivas A., Tsavaler L., Engleman E.G. J. Immunol. 159:1115-1124(1997) [PubMed: 9233604] [Abstract] Cited for: FUNCTION.
[5]	"CD101 is expressed by skin dendritic cells. Role in T-lymphocyte activation." Bagot M., Martinel I., Charue D., Weill F., Boulland M.-L., Wechsler J., Freeman G.J., Bensussan A., Boumsell L. Tissue Antigens 50:439-448(1997) [PubMed: 9389317] [Abstract] Cited for: TISSUE SPECIFICITY, FUNCTION.
[6]	"V7 (CD101) ligation inhibits TCR/CD3-induced IL-2 production by blocking Ca2+ flux and nuclear factor of activated T cell nuclear translocation." Soares L.R.B., Tsavaler L., Rivas A., Engleman E.G. J. Immunol. 161:209-217(1998) [PubMed: 9647226] [Abstract] Cited for: FUNCTION.
[7]	"Triggering CD101 molecule on human cutaneous dendritic cells inhibits T cell proliferation via IL-10 production." Bouloc A., Bagot M., Delaire S., Bensussan A., Boumsell L. Eur. J. Immunol. 30:3132-3139(2000) [PubMed: 11093127] [Abstract] Cited for: FUNCTION.
[8]	"CD101 expression by Langerhans cell histiocytosis cells." Bouloc A., Boulland M.-L., Geissmann F., Fraitag S., Andry P., Teillac D., Bensussan A., Revuz J., Boumsell L., Wechsler J., Bagot M. Histopathology 36:229-232(2000) [PubMed: 10692025] [Abstract] Cited for: TISSUE SPECIFICITY.
[9]	"EWI-2 is a major CD9 and CD81 partner and member of a novel Ig protein subfamily." Stipp C.S., Kolesnikova T.V., Hemler M.E. J. Biol. Chem. 276:40545-40554(2001) [PubMed: 11504738] [Abstract] Cited for: DOMAIN EWI MOTIF.
[10]	"CD4+ CD56+ blastic tumor cells express CD101 molecules." Meyer N., Petrella T., Poszepczynska-Guigne E., Boumsell L., Wechsler J., Bensussan A., Bagot M. J. Invest. Dermatol. 124:668-669(2005) [PubMed: 15737213] [Abstract] Cited for: FUNCTION, TISSUE SPECIFICITY.
+	Additional computationally mapped references.

Cross-references

Sequence databases
EMBL GenBank DDBJ	Z33642 mRNA. Translation: CAA83923.1. AL445231 Genomic DNA. Translation: CAH71959.1.
IPI	IPI00003531.
PIR	I39207.
RefSeq	NP_004249.2. NM_004258.3.
UniGene	Hs.654598.
3D structure databases
ProteinModelPortal	Q93033.
SMR	Q93033. Positions 24-254, 293-385, 422-580, 624-649, 758-784, 814-941.
ModBase	Search...
Protein-protein interaction databases
IntAct	Q93033. 4 interactions.
MINT	MINT-1391008.
STRING	Q93033.
PTM databases
PhosphoSite	Q93033.
Polymorphism databases
DMDM	223590070.
Proteomic databases
PRIDE	Q93033.
Protocols and materials databases
StructuralBiologyKnowledgebase	Search...
Genome annotation databases
Ensembl	ENST00000256652; ENSP00000256652; ENSG00000134256. ENST00000369470; ENSP00000358482; ENSG00000134256. ENST00000437666; ENSP00000408903; ENSG00000134256.
GeneID	9398.
KEGG	hsa:9398.
UCSC	uc009whd.1. human.
Organism-specific databases
CTD	9398.
GeneCards	GC01P117545.
H-InvDB	HIX0028852.
HGNC	HGNC:5949. CD101.
MIM	604516. gene.
neXtProt	NX_Q93033.
PharmGKB	PA165750564. PA29762.
GenAtlas	Search...
Phylogenomic databases
eggNOG	prNOG18198.
GeneTree	ENSGT00390000010278.
HOGENOM	HBG447074.
HOVERGEN	HBG107997.
InParanoid	Q93033.
OMA	QGQLFCE.
OrthoDB	EOG4V436V.
PhylomeDB	Q93033.
Gene expression databases
ArrayExpress	Q93033.
Bgee	Q93033.
CleanEx	HS_IGSF2.
Genevestigator	Q93033.
GermOnline	ENSG00000134256. Homo sapiens.
Family and domain databases
InterPro	IPR002195. Dihydroorotase_CS. IPR007110. Ig-like. IPR013783. Ig-like_fold. IPR013098. Ig_I-set. IPR003599. Ig_sub. IPR013106. Ig_V-set. [Graphical view]
Gene3D	G3DSA:2.60.40.10. Ig-like_fold. 8 hits.
KO	K06522.
Pfam	PF07679. I-set. 1 hit. PF07686. V-set. 4 hits. [Graphical view]
SMART	SM00409. IG. 7 hits. [Graphical view]
PROSITE	PS50835. IG_LIKE. 7 hits. [Graphical view]
ProtoNet	Search...
Other
NextBio	35203.
SOURCE	Search...

Entry information

Entry name

IGSF2_HUMAN

Accession

Primary (citable) accession number: Q93033
Secondary accession number(s): Q15856

Entry history

Integrated into UniProtKB/Swiss-Prot:	October 17, 2006
Last sequence update:	February 10, 2009
Last modified:	January 25, 2012
This is version 90 of the entry and version 2 of the sequence. [Complete history]

Entry status

Reviewed (UniProtKB/Swiss-Prot)

Annotation program

Chordata Protein Annotation Program

Disclaimer

Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. It is not in any way intended to be used as a substitute for professional medical advice, diagnosis, treatment or care.